Arthritis: new COX-2 inhibitor no worse for gut than placebo

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In patients with osteoarthritis (OA) and rheumatoid arthritis (RA), etoricoxib does not increase the prevalence of gastrointestinal adverse events (GAEs) compared with placebo, and may lower GAE risk compared with diclofenac (eg, Voltaren) and naproxen (eg, A...